Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database

Mian, Hira; Reece, Donna; Masih‐Khan, Esther; McCurdy, Arleigh; Kardjadj, Moustafa; Jiménez-Zepeda, Victor H; Song, Kevin; Louzada, Martha L; LeBlanc, Richard; Sébag, Michaël; White, Darrell; Stakiw, Julie; Reiman, Anthony; Kotb, Rami; Aslam, Muhammad; Gul, Engin; Venner, Christopher P.

doi:10.1016/j.clml.2022.03.002

Cited by 5 publications

(16 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The analyses conducted by Arcuri et al 20 included many treatments. Only the comparisons between treatments specified in the CADTH systematic review protocol are reported here.…”

Section: Resultsmentioning

confidence: 99%

“…The objective of Arcuri et al ( 2021) 20 was to conduct an NMA to review available evidence of novel treatments for RRMM in the setting of new drugs, and to identify the most efficacious treatment combinations.…”

Section: Objectivesmentioning

confidence: 99%

“…Refer to Arcuri et al ( 2021) 20 for a depiction of the network of evidence used for the indirect comparison.…”

Section: Summary Of Included Studiesmentioning

confidence: 99%

“…All studies were rated as having an unclear risk of bias regarding incomplete outcome data, and most studies had a high risk of bias regarding blinding of patients and personnel. 20…”

Section: Risk Of Biasmentioning

confidence: 99%

“…A forest plot depicting the results for OS are depicted in Arcuri et al (2021). 20 In general, most treatments indicated no difference.…”

Section: Overall Survivalmentioning

confidence: 99%

See 4 more Smart Citations

Selinexor (Xpovio)

CADTH¹

2022

cjht

View full text Add to dashboard Cite

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses selinexor (Xpovio) 100 mg orally. Indication: Proposed: In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 1 prior therapy.

show abstract

“…The analyses conducted by Arcuri et al 20 included many treatments. Only the comparisons between treatments specified in the CADTH systematic review protocol are reported here.…”

Section: Resultsmentioning

confidence: 99%

Section: Objectivesmentioning

confidence: 99%

“…Refer to Arcuri et al ( 2021) 20 for a depiction of the network of evidence used for the indirect comparison.…”

Section: Summary Of Included Studiesmentioning

confidence: 99%

“…All studies were rated as having an unclear risk of bias regarding incomplete outcome data, and most studies had a high risk of bias regarding blinding of patients and personnel. 20…”

Section: Risk Of Biasmentioning

confidence: 99%

“…A forest plot depicting the results for OS are depicted in Arcuri et al (2021). 20 In general, most treatments indicated no difference.…”

Section: Overall Survivalmentioning

confidence: 99%

See 3 more Smart Citations

Selinexor (Xpovio)

CADTH¹

2022

cjht

View full text Add to dashboard Cite

show abstract

Real‐world multiple myeloma front‐line treatment and outcomes by transplant in the United States

Richter

Pan

Salinardi

et al. 2023

eJHaem

View full text Add to dashboard Cite

Stem cell transplantation (SCT) has been an integral treatment modality for multiple myeloma (MM) for decades. However, as standard‐of‐care therapies have improved, the benefit of SCT has been repeatedly called into question. This retrospective study evaluated the association between SCT in the first line of therapy (LOT) and outcomes for patients with newly diagnosed multiple myeloma (NDMM) in the United States. We included patients from a de‐identified electronic health record‐derived database who initiated front‐line MM therapy between January 1, 2016, and January 31, 2022. Overall, 18.8% (1127 of 5996 patients) received SCT in the first LOT. Multivariable‐adjusted Cox proportional hazards models, in which SCT was modeled as time varying, revealed longer real‐world progression‐free survival (rwPFS; hazard ratio [HR] 0.49; 95% confidence interval [CI] 0.43–0.57) and real‐world overall survival (rwOS; HR 0.47; 95% CI 0.39–0.56) for patients who received SCT in the first LOT. The degree of rwPFS and rwOS benefit imparted by SCT was consistent across all subgroups examined, including patients aged ≥75 years, women, non‐Hispanic Black/African American patients, those with renal impairment, and those with high‐risk cytogenetics. Findings from this analysis of real‐world patients with NDMM suggest that SCT remains an important standard of care in the era of novel therapies.

show abstract

Serum proteomic profiling reveals MTA2 and AGO2 as potential prognostic biomarkers associated with disease activity and adverse outcomes in multiple myeloma

et al. 2022

View full text Add to dashboard Cite

Multiple myeloma (MM) is an incurable plasma cell malignancy accounting for approximately 10% of hematological malignancies. Identification of reliable biomarkers for better diagnosis and prognosis remains a major challenge. This study aimed to identify potential serum prognostic biomarkers corresponding to MM disease activity and evaluate their impact on patient outcomes. Serum proteomic profiles of patients with MM and age-matched controls were performed using LC–MS/MS. In the verification and validation phases, the concentration of the candidate biomarkers was measured using an ELISA technique. In addition, the association of the proposed biomarkers with clinical outcomes was assessed. We identified 23 upregulated and 15 downregulated proteins differentially expressed in newly diagnosed and relapsed/refractory MM patients compared with MM patients who achieved at least a very good partial response to treatment (≥VGPR). The top two candidate proteins, metastasis-associated protein-2 (MTA2) and argonaute-2 (AGO2), were selected for further verification and validation studies. Both MTA2 and AGO2 showed significantly higher levels in the disease-active states than in the remission states (p < 0.001). Regardless of the patient treatment profile, high MTA2 levels were associated with shorter progression-free survival (p = 0.044; HR = 2.48; 95% CI, 1.02 to 6.02). Conversely, high AGO2 levels were associated with IgG and kappa light-chains isotypes and an occurrence of bone involvement features (p < 0.05) and were associated with prolonged time to response (p = 0.045; HR = 3.00; 95% CI, 1.03 to 8.76). Moreover, the analytic results using a publicly available NCBI GEO dataset revealed that AGO2 overexpression was associated with shorter overall survival among patients with MM (p = 0.032, HR = 1.60, 95% CI, 1.04 to 2.46). In conclusion, MTA2 and AGO2 proteins were first identified as potential biomarkers that reflect disease activity, provide prognostic values and could serve as non-invasive indicators for disease monitoring and outcome predicting among patients with MM.

show abstract

Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database

Cited by 5 publications

References 26 publications

Selinexor (Xpovio)

Selinexor (Xpovio)

Real‐world multiple myeloma front‐line treatment and outcomes by transplant in the United States

Serum proteomic profiling reveals MTA2 and AGO2 as potential prognostic biomarkers associated with disease activity and adverse outcomes in multiple myeloma

Contact Info

Product

Resources

About